TAK-418

DRUG3 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Healthy ParticipantsHealthy Volunteers

Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

CompletedNCT03228433

TakedaHealthy Participants

Start: 2017-07-21End: 2018-05-12Updated: 2019-09-09

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

TerminatedNCT03501069

Millennium Pharmaceuticals, Inc.Healthy Volunteers

Start: 2018-05-30End: 2018-12-26Updated: 2020-06-16

A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants

TerminatedNCT04202497

TakedaHealthy Volunteers

Start: 2019-12-18End: 2020-03-19Updated: 2021-07-30

Related Papers

[<sup>18</sup>F]MNI-1054, a novel PET ligand for lysine-specific histone demethylase 1 A (LSD1): first-in human validation and enzyme occupancy of the LSD1 inhibitor TAK-418.

2026-07-03

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A

British Journal of Clinical Pharmacology2021-05-1522 citations